Fujian Shengdi Pharmaceutical Co., Ltd.

This phase 3 trial tests an injectable drug called ribupatide in people who have both obesity and knee osteoarthritis. The study measures whether ribupatide can reduce knee pain and stiffness, improve joint function, and help with weight loss over 68 weeks. Participants are rando…

This phase 2 study tests HRS-4729, a once-weekly injection, for weight loss in adults with obesity who do not have diabetes. About 252 participants will receive either the drug or a placebo. The main goal is to see how much body weight changes after 32 weeks compared to a placebo…

This early-stage study tests how the body processes HRS9531 tablets under different dosing conditions. It involves 100 healthy adults aged 18-55 with a BMI between 23 and 35. The goal is to measure drug levels and safety, not yet to treat weight or diabetes.

This clinical trial tests two experimental injections, HRS-4729 and HRS9531, in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition linked to obesity. The study involves 160 participants who receive either the drug or a placebo for 52 we…

This study tests an experimental drug called HRS5580, given together with a standard anti-nausea medication (palonosetron), to prevent nausea and vomiting after surgery. About 260 adults undergoing planned surgeries lasting at least 2 hours will receive one of three doses of HRS5…

This Phase 1 trial investigates how the drug HRS-9057 is absorbed, processed, and eliminated in healthy men. Six participants receive a single dose, and researchers measure the drug and its breakdown products in blood, urine, and stool. The goal is to understand the drug's behavi…